Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (PRO140)
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Sponsor: CytoDyn, Inc.
Listed as NCT02483078, this PHASE2/PHASE3 trial focuses on HIV and remains completed. Sponsored by CytoDyn, Inc., it has been updated 13 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Oct 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2_PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CytoDyn, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .